Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 298 entries
View as:

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00645593 Org: User:
Start: 03/31/08 End: 06/30/15 Due: 06/30/16

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03559049 Org: User:
Start: 12/24/18 End: 01/31/28 Due: 01/31/29

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT04858256 Org: User:
Start: 03/29/23 End: 11/30/28 Due: 11/30/29

VISmodegib for ORbital and Periocular Basal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02436408 Org: User:
Start: 07/15/15 End: 09/30/20 Due: 09/30/21

Methods for Increasing Genetic Testing Uptake in Michigan

Phase: N/A Priority: Normal
NCT ID: NCT05162846 Org: User:
Start: 04/21/22 End: 01/10/26 Due: 01/10/27

Trial Of Double Umbilical Cord Blood Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00763490 Org: User:
Start: 12/31/08 End: 10/31/15 Due: 10/31/16

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00134355 Org: User:
Start: 07/31/05 End: 03/31/07 Due: 03/31/08

Metastatic Leiomyosarcoma Biomarker Protocol

Phase: N/A Priority: Normal
NCT ID: NCT05653388 Org: User:
Start: 12/22/22 End: 12/31/26 Due: 12/31/27

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Phase: N/A Priority: Normal
NCT ID: NCT04754399 Org: User:
Start: 04/16/21 End: 10/10/23 Due: 10/10/24

A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation

Phase: N/A Priority: Normal
NCT ID: NCT02085525 Org: User:
Start: 03/31/14 End: - Due: -

Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00603057 Org: User:
Start: 05/31/07 End: 03/31/15 Due: 03/31/16

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02328755 Org: User:
Start: 01/31/15 End: 03/25/19 Due: 03/25/20

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05996107 Org: User:
Start: 02/27/24 End: 06/30/30 Due: 06/30/31

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT05956041 Org: User:
Start: 12/06/23 End: 12/31/26 Due: 12/31/27

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00724568 Org: User:
Start: 05/31/08 End: 09/03/14 Due: 09/03/15

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03689582 Org: User:
Start: 11/13/18 End: 02/27/20 Due: 02/27/21

Treatment for Patients With Metastatic Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00176748 Org: User:
Start: 07/31/05 End: 06/30/09 Due: 06/30/10

Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00456599 Org: User:
Start: 04/30/07 End: 01/31/13 Due: 01/31/14

Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02494453 Org: User:
Start: 06/30/15 End: 07/31/17 Due: 07/31/18

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT00141713 Org: User:
Start: 10/31/03 End: 12/31/06 Due: 12/31/07

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Phase: N/A Priority: Normal
NCT ID: NCT06539468 Org: User:
Start: 10/08/24 End: 12/28/25 Due: 12/28/26

Gilteritinib for the Treatment of ALK NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06225427 Org: User:
Start: 07/25/24 End: 05/31/27 Due: 05/31/28

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01469546 Org: User:
Start: 01/31/12 End: 03/31/16 Due: 03/31/17

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00115739 Org: User:
Start: 02/29/04 End: 08/31/10 Due: 08/31/11

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00151034 Org: User:
Start: 09/30/00 End: 10/31/07 Due: 10/31/08